A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
Deeply committed to providing better services to the patients and building up its prestige, Fudan University Cancer Hospital spares no effort to further explore and create opportunities for collaboration both at home and abroad. Since 2003, it has partnered with the University of Texas M.D. Anderson Cancer Center (USA), the National Health Care Group of Singapore, and the Institute of Gustave-Roussay (France), the Cancer Research Institute of Kanazawa University (Japan), and European Institute of Oncology (Italy).
Shanghai, China Clinical Trial Location
Fudan University Cancer Hospital
274 Dong’an Road, Xuhui District,
Shanghai, China, 200032